NASDAQ:MRNA (Moderna)
About MRNA
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna (NASDAQ: MRNA) Latest News

Investing
4 of the Top-Growing Stocks on Earth

Tech Stocks
Why Shopify Stock’s Steep Upside Might Be Over

Stocks for Beginners
5 Top Stocks to Buy Now for a Vaccine Breakthrough

Dividend Stocks
2 Top Stocks to Watch in September

Tech Stocks
Why Are Canadians Watching Moderna Stock Right Now?
